Publications
202
Citations
35,668
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
Lisa M. Landrum conducts clinical research in gynecologic oncology, focusing on the treatment of cancers affecting women such as endometrial (uterine lining), ovarian, and cervical cancers. Her work centers on clinical trials evaluating immunotherapy and targeted drug combinations, as well as contributing to national treatment guidelines. She also examines patient outcomes, quality of life, and biomarkers that help predict which patients will respond to specific therapies.
Publication activity has grown considerably over the past decade, with a notable increase from 2023 onward and an average of about 14 publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~18 · 3% small-team papers (≤3 authors) · across 27 venues
- Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2026
- Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
Journal of Clinical Oncology · 2026
- A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer.
Journal of Clinical Oncology · 2026
- Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.
Journal of Clinical Oncology · 2026
- Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence
JCO Precision Oncology · 2025
- PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY
International Journal of Gynecological Cancer · 2025
- Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Nature Medicine · 2025
- Abstract A040: MYC-HSF1 coamplification as a biomarker for treatment sensitivity in high-grade serous ovarian cancer
Cancer Research · 2025
- MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer
Cancer Research Communications · 2025
- Thematic cultural heritage tourism trail planning integrating multi-source data and machine learning in Wuhan China
npj Heritage Science · 2025
- Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up
International Journal of Gynecological Cancer · 2025
- A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
PubMed · 2025
- Comparison of the Clinical and Genomic Profiles of Endometrial Cancer in Appalachian and Non-Appalachian Patients
SSRN Electronic Journal · 2025
- 46P Time to next treatment by age subgroup in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
ESMO Open · 2025
- Machine learning approach for risk-based prediction of endometrial cancer recurrence
Gynecologic Oncology · 2025
- Gynecologic Oncology×28
- International Journal of Gynecological Cancer×11
- Journal of Clinical Oncology×10
- Annals of Oncology×4
- Elsevier eBooks×4
- Larry J. Copeland
Medicine · The Ohio State University
- Kristin Bixel
Medicine · The Ohio State University
- Quinn Kistenfeger
Medicine · The Ohio State University
- Casey Cosgrove
Medicine · The Ohio State University
- Corinne Calo
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile